Isolated DNA Declared Patentable By US Court Of Appeals17/08/2012 by Intellectual Property Watch 3 CommentsShare this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)IP-Watch is a non-profit independent news service and depends on subscriptions. To access all of our content, please subscribe now. You may also offer additional support with your subscription, or donate.By Catherine Saez for Intellectual Property WatchThe United States Court of Appeals for the Federal Circuit released a decision today (16 August) on the patentability of genes in yet another twist to the so-called Myriad case. At stake was the patentability of two human genes associated with hereditary breast cancer and ovarian cancer. Myriad Genetics’ patents were challenged by the Association for Molecular Pathology.The decision is available here [pdf].In a 2-1 decision, the Court of Appeals decided to partially reverse a lower court’s ruling, according to a press release of the American Civil Liberties Union (ACLU).Myriad Genetics hailed the decision. “Importantly, the Court agreed with Myriad that isolated DNA is a new chemical matter with important utilities which can only exist as the product of human ingenuity,” Myriad President and CEO Peter Meldrum said in a release.In March, the US Supreme Court remanded the case back to the Federal Circuit for further consideration, after the high court’s decision a few days before, on another case called Mayo Collaborative Services v. Prometheus Laboratories (IPW, IP Live, 27 March 2012).The court ruled that isolated DNA molecules were parent eligible as were method claims to screening potential cancer therapeutics via changes in cell growth rates of transformed cells. It ruled, however that method claims which compare or analyse two gene sequences are not parent eligible.The decision is considered a setback by the ACLU. Staff Attorney with the ACLU Women’s Rights Project, Sandra Park, said “This is a devastating decision for a women’s health,” in the release, referring to the monopoly of Myriad over the genes. According to the ACLU, this allows Myriad “to set the terms and cost of testing and makes it impossible for women to access alternate tests or get a comprehensive second opinion about their results.” The ACLU also said this monopoly hindered further research on the genes.Myriad denied that patents have hindered research on the two incriminated genes (BRCA1 and BRCA2) as the company never “denied, opposed or impeded any research studies” on those genes. In the same release, they said the cost of BRCA testing “is not prohibitive and patient access is extensive,” adding that patients could access the text “through private insurance, Medicare, Medicaid or Myriad’s Financial Assistance Program, which provides coverage at no charge to low-income, uninsured patients.”The case should go back to the Supreme Court later this year, according to attorney Harold Wegner.Share this Story:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Google+ (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)Related"Isolated DNA Declared Patentable By US Court Of Appeals" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.